Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida
Levi, R.; Mansuri, F.; Jordan, M.; Ladapo, J.
Show abstract
Comparative effects of the mRNA COVID-19 vaccines on mortality and other health outcomes are uncertain. Matched cohort analysis of 1,962,822 adults living in Florida who received a first dose of either BNT162b2 (Pfizer) or mRNA-1273 (Moderna) between December 18, 2020, and August 31, 2021, was used to examine 12-month risk of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality. Matching was performed on seven criteria, including census tract. Compared with mRNA-1273 recipients, BNT162b2 recipients had significantly higher risk for all-cause mortality (783.6 vs. 562.4 deaths per 100,000; odds ratio, OR [95% CI]: 1.407 [1.358, 1.457]), cardiovascular mortality, COVID-19 mortality and non-COVID-19 mortality. Negative control outcomes and robustness analyses did not show any indication of meaningful unobserved residual confounding that is likely to alter the results. The results of this study are consistent with cumulative evidence from prior literature showing worse outcomes in recipients of BNT162b2 compared to mRNA-1273. Primary Funding SourceThe study did not receive any external funding.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims 96%
- Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S. 96%
- Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older 96%
Similar papers in this journal
Similar papers in this journal
- Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults With Underlying Medical Conditions in the United States 95%
- Race-ethnicity and Perceptional Determinants of COVID-19 Vaccination Intentions: A Cross-sectional Study Among Health Workers and the General Population in the San Francisco Bay Area 94%
- Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021 94%
Similar papers in this journal
- Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era 94%
- Real-world Effectiveness of BNT162b2 in Children and Adolescents in Preventing Infection and Severe Diseases with SARS-CoV-2 During the Delta and Omicron Periods: Findings from Trial Emulation Using an EHR-based Cohort 94%
- Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials 94%
Similar papers in this journal
- Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study 95%
- Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. Adults 94%
- Time trends, factors associated with, and reasons for COVID-19 vaccine hesitancy in a massive online survey of US adults: January-May 2021 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.